About the ABPI

The ABPI represents innovative resea​rch-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.

Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. We represent companies who supply more than 80 per cent of all branded medicines used by the NHS and who are researching and developing the majority of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome disease.

Globally our industry is researching and developing more than 7,000 new medicines.

The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry for statutory consultation requirements including the pricing scheme for medicines in the UK.​​​​​​​

  1. Erik Nordkamp has been Managing Director at Pfizer UK since March 2015 and originally joined Pfizer in 2010, serving as Head of Strategy for Primary Care Europe and Canada at Pfizer in the UK. He also served as President of PhRMA Innovation, the global trade association for the pharmaceutical industry, where he led the transformation of the forum, positioning it as the main representative body for the innovative pharmaceutical industry in Greece. He has been a Non-Executive Director of King's College Hospital NHS Foundation Trust since January 2016 and is currently Chair of the American Pharmaceutical Group.
  2. Haseeb Ahmad joined Novartis as Managing Director, UK & Ireland for Pharmaceuticals, and Country President UK, in February 2017, and was elected to the ABPI Board shortly after. In his prior role with MSD, as Managing Director for Greece, he delivered significant growth through a period of major economic upheavals, he also led the relevant industry association, the American Chamber of Commerce Pharma Group. During his twenty-year career, Haseeb has held progressively senior in-country and above-country roles in Strategy, Operations, Sales and Marketing.

Media enquiries

+44 (0) 20 7747 7147​​